IL261316B2 - Compositions and methods for cd20 immunotherapy - Google Patents

Compositions and methods for cd20 immunotherapy

Info

Publication number
IL261316B2
IL261316B2 IL261316A IL26131618A IL261316B2 IL 261316 B2 IL261316 B2 IL 261316B2 IL 261316 A IL261316 A IL 261316A IL 26131618 A IL26131618 A IL 26131618A IL 261316 B2 IL261316 B2 IL 261316B2
Authority
IL
Israel
Prior art keywords
cells
cell
fusion protein
seq
polynucleotide
Prior art date
Application number
IL261316A
Other languages
English (en)
Hebrew (he)
Other versions
IL261316B1 (en
IL261316A (en
Original Assignee
Hutchinson Fred Cancer Res
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res, Fred Hutchinson Cancer Center filed Critical Hutchinson Fred Cancer Res
Publication of IL261316A publication Critical patent/IL261316A/en
Publication of IL261316B1 publication Critical patent/IL261316B1/en
Publication of IL261316B2 publication Critical patent/IL261316B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL261316A 2016-03-18 2017-03-17 Compositions and methods for cd20 immunotherapy IL261316B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310541P 2016-03-18 2016-03-18
US201662320327P 2016-04-08 2016-04-08
PCT/US2017/023098 WO2017161353A1 (en) 2016-03-18 2017-03-17 Compositions and methods for cd20 immunotherapy

Publications (3)

Publication Number Publication Date
IL261316A IL261316A (en) 2018-10-31
IL261316B1 IL261316B1 (en) 2024-01-01
IL261316B2 true IL261316B2 (en) 2024-05-01

Family

ID=58448653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL261316A IL261316B2 (en) 2016-03-18 2017-03-17 Compositions and methods for cd20 immunotherapy

Country Status (14)

Country Link
US (2) US10875927B2 (enExample)
EP (2) EP3939994A3 (enExample)
JP (2) JP7065782B2 (enExample)
KR (2) KR102499191B1 (enExample)
CN (1) CN108884144B (enExample)
AU (1) AU2017235657B2 (enExample)
BR (1) BR112018067977A8 (enExample)
CA (1) CA3015369A1 (enExample)
DK (1) DK3430038T3 (enExample)
ES (1) ES2893840T3 (enExample)
IL (1) IL261316B2 (enExample)
MX (1) MX2018010415A (enExample)
NZ (1) NZ744913A (enExample)
WO (1) WO2017161353A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
CN105985444B (zh) * 2015-02-05 2024-02-13 博生吉安科细胞技术有限公司 一种嵌合抗原受体、以及快速构建嵌合抗原受体的方法及应用
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
AU2019216269B2 (en) * 2018-01-30 2025-05-01 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen
CN112368021B (zh) 2018-06-14 2025-02-21 2赛文缇生物公司 Cd79a嵌合抗原受体
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
CN109293781A (zh) * 2018-09-12 2019-02-01 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
CN112840026B (zh) * 2018-10-18 2025-01-14 施能康公司 抑制tigit基因表达的组合物和方法
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
WO2020180648A1 (en) * 2019-03-01 2020-09-10 Gritstone Oncology, Inc. Selection of t cell receptors
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
MX2021015495A (es) * 2019-06-14 2022-04-18 2Seventy Bio Inc Composiciones y métodos para tratar cáncer.
AU2020315213A1 (en) * 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
US20220411479A1 (en) * 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
CN111944062B (zh) * 2019-12-09 2023-11-07 深圳市体内生物医药科技有限公司 一种识别Fc片段的嵌合抗原受体及其应用
KR20220149606A (ko) * 2020-03-02 2022-11-08 더 리전츠 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 키메라 항원 수용체 및 관련 방법 및 조성물
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021231959A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
WO2021231954A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
CN114774364B (zh) * 2022-04-26 2024-04-26 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
CN117343176A (zh) * 2022-07-04 2024-01-05 上海优卡迪生物医药科技有限公司 人源化的结合cd20的抗体或cd20抗原结合片段及应用
WO2024097313A1 (en) * 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Methods for producing t cell therapy products
PE20260290A1 (es) 2023-03-31 2026-02-10 Abelzeta Inc Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
WO2026073918A1 (en) * 2024-10-02 2026-04-09 Galapagos Nv Novel anti-cd20 binding domains and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410319B1 (en) * 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2006130458A2 (en) * 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to cd20 and uses thereof
CN105330750A (zh) * 2015-11-20 2016-02-17 上海细胞治疗研究院 一种快速中止car-t细胞杀伤作用的分子刹车及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
KR20100102172A (ko) 2007-12-21 2010-09-20 제넨테크, 인크. 리툭시마브-난치성 류마티스성 관절염 환자의 요법
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) * 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
US20140004037A1 (en) 2012-01-19 2014-01-02 Therapeutic Proteins, Inc. Stabilization of the anti-cd20 antibody rituximab
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
KR102185175B1 (ko) 2012-11-02 2020-12-02 티지 쎄라퓨틱스, 인코포레이티드 항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015042807A1 (zh) * 2013-09-25 2015-04-02 北京安保康生物医药科技有限公司 抗cd20的全人源单克隆抗体及其应用
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
JP6831777B2 (ja) * 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410319B1 (en) * 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2006130458A2 (en) * 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to cd20 and uses thereof
CN105330750A (zh) * 2015-11-20 2016-02-17 上海细胞治疗研究院 一种快速中止car-t细胞杀伤作用的分子刹车及其用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUDDE, LIHUA E., ET AL., COMBINING A CD20 CHIMERIC ANTIGEN RECEPTOR AND AN INDUCIBLE CASPASE 9 SUICIDE SWITCH TO IMPROVE THE EFFICACY AND SAFETY OF T CELL ADOPTIVE IMMUNOTHERAPY FOR LYMPHOMA., 17 December 2013 (2013-12-17) *
G. A. RUFENER ET AL,, PRESERVED ACTIVITY OF CD20-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS IN THE PRESENCE OF RITUXIMAB, 21 April 2016 (2016-04-21) *
LIHUA E. BUDDE ET AL,, COMBINING A CD20 CHIMERIC ANTIGEN RECEPTOR AND AN INDUCIBLE CASPASE 9 SUICIDE SWITCH TO IMPROVE THE EFFICACY AND SAFETY OF T CELL ADOPTIVE IMMUNOTHERAPY FOR LYMPHOMA, 17 December 2013 (2013-12-17) *
RUFENER GREGORY A ET AL,, 4428: PRESERVATION OF CD20-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL FUNCTION IN THE PRESENCE OF RESIDUAL RITUXIMAB, 3 December 2015 (2015-12-03) *

Also Published As

Publication number Publication date
BR112018067977A2 (pt) 2019-02-05
KR20180127348A (ko) 2018-11-28
KR102499191B1 (ko) 2023-02-13
IL261316B1 (en) 2024-01-01
AU2017235657A1 (en) 2018-09-06
JP2019515652A (ja) 2019-06-13
MX2018010415A (es) 2018-11-29
IL261316A (en) 2018-10-31
NZ744913A (en) 2025-09-26
CN108884144B (zh) 2023-03-14
KR102366611B1 (ko) 2022-02-23
EP3939994A3 (en) 2022-04-27
US20190106501A1 (en) 2019-04-11
RU2018134300A (ru) 2020-04-20
WO2017161353A1 (en) 2017-09-21
US10875927B2 (en) 2020-12-29
KR20220030307A (ko) 2022-03-10
JP2022002550A (ja) 2022-01-11
CA3015369A1 (en) 2017-09-21
EP3430038B1 (en) 2021-06-16
EP3430038A1 (en) 2019-01-23
BR112018067977A8 (pt) 2023-04-11
RU2018134300A3 (enExample) 2020-07-15
US20210147569A1 (en) 2021-05-20
JP7065782B2 (ja) 2022-05-12
DK3430038T3 (da) 2021-09-13
ES2893840T3 (es) 2022-02-10
CN108884144A (zh) 2018-11-23
AU2017235657B2 (en) 2022-07-21
EP3939994A2 (en) 2022-01-19
JP7397840B2 (ja) 2023-12-13
US11834511B2 (en) 2023-12-05

Similar Documents

Publication Publication Date Title
US11834511B2 (en) Compositions and methods for CD20 immunotherapy
US20240166758A1 (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
JP7599205B2 (ja) 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
JP2024167225A (ja) キメラ抗原受容体とｐｄ－１阻害薬との併用療法
US20210347851A1 (en) Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
CN105392888B (zh) 使用人源化抗cd19嵌合抗原受体治疗癌症
US20200262894A1 (en) Strep-tag specific binding proteins and uses thereof
HK40067523A (en) Compositions and methods for cd20 immunotherapy
HK40003185B (en) Compositions and methods for cd20 immunotherapy
RU2799762C2 (ru) Комбинированная терапия для лечения связанных с bcma раковых заболеваний и аутоиммунных расстройств
HK40019036B (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
HK40019036A (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
NZ756241B2 (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders